ALXN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Stats
Today's Volume	3.00
Average Volume	4.22M
Market Cap	0.00
EPS	$0 ( 2021-07-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	59.23
ATR14	$1.935 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-21	Coughlin Christopher J	Sell	42 347	Common Stock, par value $.0001 per share
2021-07-21	Coughlin Christopher J	Sell	2 294	Option to Purchase Common Stock
2021-07-21	Coughlin Christopher J	Sell	2 706	Option to Purchase Common Stock
2021-07-21	Coughlin Christopher J	Sell	2 343	Option to Purchase Common Stock
2021-07-21	Sarin Aradhana	Sell	120 253	Common Stock, par value $.0001 per share

INSIDER POWER
0.00
Last 100 transactions
Buy: 1 094 307 \| Sell: 1 860 897

Volume Correlation

Long: 0.13 (neutral)

Short: 0.11 (neutral)

Signal:(52.183) Neutral

Alexion Pharmaceuticals, Correlation

10 Most Positive Correlations
CREC	0.977
LDHA	0.976
PRSR	0.976
MSDAU	0.973
PWUP	0.973
IXAQ	0.972
CRZN	0.972
IGTA	0.97
VLAT	0.97
AEAE	0.969

10 Most Negative Correlations
FUV	-0.983
MESA	-0.979
MBIO	-0.979
JG	-0.977
MLKN	-0.975
RENT	-0.974
NXTC	-0.974
GERN	-0.974
ASRV	-0.973
CNTY	-0.973

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alexion Pharmaceuticals, Correlation - Currency/Commodity

0.87
( strong )

0.83
( strong )

0.39
( neutral )

0.44
( neutral )

0.64
( weak )

-0.72
( moderate negative )

Alexion Pharmaceuticals, Financials

Annual	2020
Revenue:	$6.07B
Gross Profit:	$5.52B (90.88 %)
EPS:	$2.74

Q1	2021
Revenue:	$1.64B
Gross Profit:	$1.51B (92.34 %)
EPS:	$2.89

Q4	2020
Revenue:	$1.59B
Gross Profit:	$1.44B (90.44 %)
EPS:	$2.45

Q3	2020
Revenue:	$1.59B
Gross Profit:	$1.44B (90.89 %)
EPS:	$2.64

Financial Reports:

No articles found.

Alexion Pharmaceuticals,

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.